Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study

Monge, Susana; Humphreys, James; Nicolay, Nathalie; Braeye, Toon; Van Evercooren, Izaak; Holm Hansen, Christian; Emborg, Hanne‐Dorthe; Sacco, Chiara; Mateo‐Urdiales, Alberto; Castilla, Jesús; Martínez‐Baz, Iván; de Gier, Brechje; Hahné, Susan; Meijerink, Hinta; Kristoffersen, Anja Bråthen; Machado, Ausenda; Soares, Patricia; Nardone, Anthony; Bacci, Sabrina; Kissling, Esther; Nunes, Baltazar

http://hdl.handle.net/10400.18/10409

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Influenza Resp Viruses - 2024 - Monge - Effectiveness of XBB 1 5 Monovalent COVID‐19 Vaccines During a Period of XBB 1 5.pdf		1.39 MB	Adobe PDF	Download

Send Feedback

Authors

Van Evercooren, Izaak

Holm Hansen, Christian

Emborg, Hanne‐Dorthe

Sacco, Chiara

Mateo‐Urdiales, Alberto

Castilla, Jesús

Abstract(s)

Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65- to 79-year-olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.

Keywords

COVID-19 SARS‐CoV‐2 Cohort Design Electronic Health Records Vaccine Effectiveness Hospitalisation Multicountry Study VEBIS-Lot 4 Europe Vacina COVID-19 Efetividade Registos Eletrónicos em Saúde Cuidados de Saúde Infecções Respiratórias